Earnings summaries and quarterly performance for Natera.
Executive leadership at Natera.
Steven Chapman
Detailed
Chief Executive Officer and President
CEO
DR
Daniel Rabinowitz
Detailed
Chief Legal Officer and Secretary
JF
John Fesko
Detailed
President, Chief Business Officer
MR
Matthew Rabinowitz
Detailed
Executive Chairman
MB
Michael Brophy
Detailed
Chief Financial Officer
SM
Solomon Moshkevich
Detailed
President, Clinical Diagnostics
Board of directors at Natera.
Research analysts who have asked questions during Natera earnings calls.
Daniel Brennan
TD Cowen
5 questions for NTRA
Also covers: A, ADPT, AVTR +24 more
PS
Puneet Souda
Leerink Partners
5 questions for NTRA
Also covers: A, ABCL, BRKR +20 more
Catherine Schulte
Baird
4 questions for NTRA
Also covers: A, CSTL, EXAS +7 more
Tycho Peterson
Jefferies
4 questions for NTRA
Also covers: A, AVTR, BIO +22 more
RV
Rachel Vatnsdal Olson
JPMorgan
3 questions for NTRA
Also covers: A, ADPT, AKYA +14 more
TS
Tejas Savant
Morgan Stanley
3 questions for NTRA
Also covers: ADPT, AKYA, AVTR +19 more
Douglas Schenkel
Wolfe Research, LLC
2 questions for NTRA
Also covers: A, AVTR, BRKR +21 more
Doug Schenkel
Wolfe Research LLC
2 questions for NTRA
Also covers: A, AVTR, BRKR +15 more
CW
Casey Woodring
JPMorgan Chase & Co.
1 question for NTRA
Also covers: A, BLLN, CRL +10 more
CB
Colleen Babington
Wolfe Research, LLC
1 question for NTRA
Also covers: CARS, GRAL, TEM +1 more
DL
Daniel Leonard
Stifel Financial Corp.
1 question for NTRA
Also covers: A, AVTR, BIO +15 more
MS
Matthew Sykes
Goldman Sachs Group Inc.
1 question for NTRA
Also covers: A, ADPT, AVTR +21 more
MS
Matt Sykes
Goldman Sachs Group, Inc.
1 question for NTRA
Also covers: CRL, CTKB, MRVI +4 more
Noah
Jefferies
1 question for NTRA
Rachel Vatnsdal
JPMorgan Chase & Co.
1 question for NTRA
Also covers: A, AKYA, AVTR +11 more
Subbu Nambi
Guggenheim Securities
1 question for NTRA
Also covers: BOLD, BRKR, CARS +16 more
SN
Subhalaxmi Nambi
Guggenheim Securities
1 question for NTRA
Also covers: AKYA, BRKR, CSTL +15 more
Recent press releases and 8-K filings for NTRA.
Natera presents initial Phase III PALLAS study results for Signatera™ MRD testing
NTRA
New Projects/Investments
Product Launch
- Natera (NTRA) announced initial translational research results from the international randomized Phase III PALLAS study, demonstrating that its Signatera™ molecular residual disease (MRD) testing provides powerful post-surgical prognostic information in patients with high and intermediate risk HR+/HER2- breast cancer.
- The findings, presented at the San Antonio Breast Cancer Symposium (SABCS), indicate that MRD status after surgery is a highly prognostic biomarker for distant recurrence risk in stage II–III, HR+/HER2- breast cancer.
- At baseline, MRD-negative patients had excellent outcomes, with a 5-year distant recurrence-free interval (DRFI) of 93%, underscoring an exceptionally low risk of distant recurrence.
- Conversely, MRD-positive patients at baseline had very poor outcomes, with a 5-year DRFI of 28%, corresponding to a markedly elevated hazard of distant recurrence (hazard ratio [HR] ~15) compared to MRD-negative patients.
- Signatera ctDNA status consistently showed strong prognostic value across all postoperative timepoints tested, with MRD-positive patients having hazard ratios between 13.4 and 21.5 compared with MRD-negative patients.
Dec 11, 2025, 12:57 AM
Natera Highlights New Lymphoma Findings at ASH Annual Meeting
NTRA
- Natera presented new findings at the American Society of Hematology (ASH) Annual Meeting, highlighting the value of personalized circulating tumor DNA (ctDNA) testing in lymphoma.
- A real-world Signatera™ analysis showed 94% of lymphoma patients had detectable ctDNA in a pre-treatment sample, and ctDNA clearance during treatment was highly predictive of CAR-T response.
- Signatera status at the end of first-line therapy was highly prognostic of event-free survival (HR: 49.77, p<0.0001), outperforming standard of care PET-CT response assessment across lymphoma subtypes.
- Results from the HOVON study, utilizing the CLARITY ctDNA assay, demonstrated that early molecular response was associated with improved clinical outcomes in diffuse large B-cell lymphoma patients.
- Following any negative ctDNA test during surveillance in the HOVON study, the probability of remaining relapse-free was 99% at 6 months and 97% at 12 months.
Dec 9, 2025, 1:00 PM
Natera acquires Foresight Diagnostics
NTRA
M&A
New Projects/Investments
- Natera, Inc. completed the acquisition of Foresight Diagnostics Inc. on December 4, 2025, a cancer diagnostics company specializing in molecular residual disease (MRD) detection.
- The acquisition was an all-stock transaction, consisting of a $275 million upfront payment and an additional $175 million in earnouts tied to revenue- and reimbursement-based milestones.
- This strategic move is expected to expand Natera's leadership in solid tumor MRD, integrate Foresight's ultrasensitive phased variant technology, and accelerate Natera's presence in the lymphoma market.
Dec 5, 2025, 1:01 PM
Natera Reports Strong Q3 2025 Performance and Outlines Growth Strategy
NTRA
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Natera achieved outstanding Q3 2025 financial results, with revenue exceeding $500 million for the first time, a record 200,000 clinical units, and 64.9% gross margins.
- The company projects its MRD business (Signatera) to surpass $1 billion in revenue within the next two to three years, with strong growth anticipated into 2026 and beyond due to early market penetration.
- Natera expects continued growth in Women's Health and Organ Health, targeting mid-single-digit volume growth and stable average selling prices (ASPs) for 2026, while Signatera's realized pricing is expected to improve through expanded coverage.
- The company has seven submissions to MolDX prepared to expand Signatera coverage across additional tumor types, which is expected to enhance average selling prices.
- Signatera demonstrated "absolutely phenomenal" results in the IMvigor011 trial for muscle-invasive bladder cancer, showing an overall survival signal and indicating a significant shift in treatment approaches.
Dec 3, 2025, 1:00 PM
Natera Reports Strong Q3 Performance and Outlines Growth Prospects
NTRA
Revenue Acceleration/Inflection
New Projects/Investments
Guidance Update
- Natera reported record Q3 performance with revenue exceeding $500 million and record gross margins of 64.9% (or 61.3% adjusted for true-ups).
- The company's MRD (Signatera) business has over $500 million in revenue, is growing double-digits, and is projected to exceed $1 billion in the next two to three years.
- Natera anticipates continued strong growth into 2026 and beyond, driven by stable sales teams in Women's Health and Organ Health, and improving average selling prices (ASPs).
- Significant progress is being made in expanding Signatera's reimbursement, with seven submissions ready for MolDX to broaden coverage across more tumor types.
- The IMvigor011 trial showed "phenomenal" overall survival results for Signatera-positive muscle-invasive bladder cancer patients, representing a "sea change" in treatment.
Dec 3, 2025, 1:00 PM
Natera Discusses Strong Q3 2025 Results and Future Growth Drivers
NTRA
Revenue Acceleration/Inflection
New Projects/Investments
Guidance Update
- Natera reported an outstanding Q3 2025, with revenue cresting above $500 million for the first time, record clinical signature units, and record gross margins of 64.9% (61.3% organic).
- The company anticipates its MRD business (Signatera) will exceed $1 billion in revenue within the next 2-3 years, driven by double-digit growth and early market penetration.
- Natera has seven submissions to MolDX for expanded Signatera coverage across additional tumor types, which is expected to improve average selling prices (ASPs).
- The IMvigor011 trial demonstrated an overall survival signal for atezolizumab in Signatera-positive muscle-invasive bladder cancer patients, with data published in the New England Journal of Medicine.
- Preliminary results from the PROCEED trial for early cancer detection in advanced adenomas showed a sensitivity of circa 22%, with the next update expected from the FIND study in 2027.
Dec 3, 2025, 1:00 PM
Natera Discusses Strong Q3 Performance, Signatera Growth, and Future Investments
NTRA
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Natera reported an outstanding Q3, beating revenue expectations by $25 million (excluding true-ups) and increasing full-year guidance by $160 million, now tracking to 30% growth.
- The company anticipates launching Signatera in Japan in 2027, which could effectively double the annual volume Total Addressable Market (TAM).
- Natera is making significant investments in early cancer detection, with the trial alone expected to cost more than $40 million to $50 million incrementally next year, following "extremely promising" preliminary data.
- The company has achieved cash flow break-even by mid-2024 and is now sustainably generating cash.
- Natera is pursuing seven MolDX submissions by year-end, which could cover approximately 30% of current Medicare volume not yet reimbursed, representing an incremental upside opportunity for Average Selling Prices (ASPs).
Nov 19, 2025, 3:00 PM
Natera Discusses Strong Q3 Performance, Signatera Growth, and Future Investments
NTRA
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Natera reported an outstanding Q3, exceeding revenue expectations by $25 million and raising full-year guidance by $160 million, projecting 30% growth.
- The company's Signatera product is experiencing a "massive ramp" in utilization, with a long-term goal of $5 billion in annual sales and gross margins approaching 70%.
- Natera is aggressively investing in early cancer detection, with promising preliminary data for colorectal cancer screening and plans for a large FDA-enabling study, which will incur costs "more than" $40 million to $50 million next year.
- International expansion plans include a 2027 launch of Signatera in Japan, which could effectively double the annual volume Total Addressable Market (TAM).
- The company has achieved cash flow break-even by mid-2024 and is now sustainably generating cash, even after significantly expanding R&D and commercial operations.
Nov 19, 2025, 3:00 PM
Natera Discusses Strong Q3 Performance and Future Growth Initiatives
NTRA
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Natera reported an outstanding Q3, exceeding revenue expectations by $25 million (excluding true-ups) and raising its full-year guidance by $160 million, now projecting 30% growth.
- The company is experiencing a "massive ramp" in the utilization of its Signatera product, which is becoming a standard in cancer patient care, alongside outstanding revenue growth in its women's health business.
- Natera has a long-term goal for Signatera to reach $5 billion in annual sales with gross margins approaching 70%, and plans a 2027 launch in Japan, potentially doubling the annual volume Total Addressable Market (TAM).
- Significant investments are being made in early cancer detection, including an FDA-enabling study with an incremental spend of more than $30-$50 million next year.
- The company anticipates achieving cash flow break-even by mid-2024 and sustainably generating cash flow thereafter.
Nov 19, 2025, 3:00 PM
Natera Highlights Q3 Growth, $200M Revenue Opportunity, and Early Cancer Detection Progress
NTRA
Product Launch
New Projects/Investments
Guidance Update
- Natera reported record Q3 clinical MRD volumes for Signatera, with strong momentum continuing into Q4, driven by clinical data including the Vigor 011 study in muscle invasive bladder cancer which showed an overall survival result and was published in the New England Journal.
- The company anticipates $200 million in annualized incremental revenue and gross profit from submitting seven additional MolDX applications for currently uncovered indications in Q4, aiming to improve average selling price and gross margin.
- Natera is advancing its early cancer detection program, with the 40,000-patient FDA-enabling FIND study for colorectal cancer expected to complete recruitment in 2026 and submit to the FDA in 2027.
- The CFO highlighted the company's path to profitability, noting $100 million in free cash flow generated this year and a projected 10% operating expense growth next year against an estimated 16% revenue growth.
- Natera recently launched the 20-gene Fetal Focus assay for NIPT, which screens for inherited disorders directly from cell-free fetal DNA, addressing situations where the father is unavailable for screening.
Nov 18, 2025, 1:00 PM
Quarterly earnings call transcripts for Natera.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more